实用药物与临床
實用藥物與臨床
실용약물여림상
PRACTICAL PHARMACY AND CLINICAL REMEDIES
2015年
5期
548-551
,共4页
张擎%李翔%陈惠裕%王爱
張擎%李翔%陳惠裕%王愛
장경%리상%진혜유%왕애
依托咪酯%利多卡因%老年患者%无痛肠镜
依託咪酯%利多卡因%老年患者%無痛腸鏡
의탁미지%리다잡인%노년환자%무통장경
Etomidate%Lidocaine%Elderly patient%Painless colonoscopy
目的:评价利多卡因联合依托咪酯在老年人无痛肠镜检查中的应用效果及安全性。方法选择150例行无痛肠镜检查的老年患者,采用随机数字表法分为3组,每组50例:利多卡因联合依托咪酯组( LE组)、芬太尼联合依托咪酯组( FE组)和芬太尼联合丙泊酚组( FP组)。采用双盲法分别给予相应麻醉药物,待患者睫毛反射消失后停止注射,行肠镜检查术。持续监测并记录两组患者给药前(T0)、检查开始时(T1)、肠镜至回盲瓣时(T2)、术毕时(T3)、苏醒时(T4)的平均动脉压(MAP)、呼吸频率(RR)、心率(HR)和脉搏氧饱和度( SpO2)等生命体征的变化。记录麻醉诱导时间、肠镜检查时间、术后苏醒时间、阿托品和麻黄碱使用情况;记录术中呼吸暂停、心动过缓、低氧血症、肌阵挛、注射痛、低血压及术后有关并发症的发生情况。结果与LE组比较,FP组T1时MAP、HR 及 T1~T2时 RR 明显降低[(69.7±11.1) mmHg vs.(88.6±11.2) mmHg;(61.3±10.3)次/min vs.(73.4±7.7)次/min;(8.4±2.6)次/min vs.(17.5±4.1)次/min;(10.1±3.2)次/min vs.(18.0±2.5)次/min,P均<0.05];与 FE 组相比,FP 组 T1时 HR、RR 及 T2时 RR 均明显降低[(61.3±10.3)次/min vs.(70.2±9.8)次/min;(8.4±2.6)次/min vs.(16.1±2.4)次/min;(10.1±3.2)次/min vs.(16.6±3.1)次/min,P均<0.05]。结论利多卡因联合依托咪酯用于老年人无痛肠镜检查麻醉效果满意,不良反应少,值得临床推广。
目的:評價利多卡因聯閤依託咪酯在老年人無痛腸鏡檢查中的應用效果及安全性。方法選擇150例行無痛腸鏡檢查的老年患者,採用隨機數字錶法分為3組,每組50例:利多卡因聯閤依託咪酯組( LE組)、芬太尼聯閤依託咪酯組( FE組)和芬太尼聯閤丙泊酚組( FP組)。採用雙盲法分彆給予相應痳醉藥物,待患者睫毛反射消失後停止註射,行腸鏡檢查術。持續鑑測併記錄兩組患者給藥前(T0)、檢查開始時(T1)、腸鏡至迴盲瓣時(T2)、術畢時(T3)、囌醒時(T4)的平均動脈壓(MAP)、呼吸頻率(RR)、心率(HR)和脈搏氧飽和度( SpO2)等生命體徵的變化。記錄痳醉誘導時間、腸鏡檢查時間、術後囌醒時間、阿託品和痳黃堿使用情況;記錄術中呼吸暫停、心動過緩、低氧血癥、肌陣攣、註射痛、低血壓及術後有關併髮癥的髮生情況。結果與LE組比較,FP組T1時MAP、HR 及 T1~T2時 RR 明顯降低[(69.7±11.1) mmHg vs.(88.6±11.2) mmHg;(61.3±10.3)次/min vs.(73.4±7.7)次/min;(8.4±2.6)次/min vs.(17.5±4.1)次/min;(10.1±3.2)次/min vs.(18.0±2.5)次/min,P均<0.05];與 FE 組相比,FP 組 T1時 HR、RR 及 T2時 RR 均明顯降低[(61.3±10.3)次/min vs.(70.2±9.8)次/min;(8.4±2.6)次/min vs.(16.1±2.4)次/min;(10.1±3.2)次/min vs.(16.6±3.1)次/min,P均<0.05]。結論利多卡因聯閤依託咪酯用于老年人無痛腸鏡檢查痳醉效果滿意,不良反應少,值得臨床推廣。
목적:평개리다잡인연합의탁미지재노년인무통장경검사중적응용효과급안전성。방법선택150례행무통장경검사적노년환자,채용수궤수자표법분위3조,매조50례:리다잡인연합의탁미지조( LE조)、분태니연합의탁미지조( FE조)화분태니연합병박분조( FP조)。채용쌍맹법분별급여상응마취약물,대환자첩모반사소실후정지주사,행장경검사술。지속감측병기록량조환자급약전(T0)、검사개시시(T1)、장경지회맹판시(T2)、술필시(T3)、소성시(T4)적평균동맥압(MAP)、호흡빈솔(RR)、심솔(HR)화맥박양포화도( SpO2)등생명체정적변화。기록마취유도시간、장경검사시간、술후소성시간、아탁품화마황감사용정황;기록술중호흡잠정、심동과완、저양혈증、기진련、주사통、저혈압급술후유관병발증적발생정황。결과여LE조비교,FP조T1시MAP、HR 급 T1~T2시 RR 명현강저[(69.7±11.1) mmHg vs.(88.6±11.2) mmHg;(61.3±10.3)차/min vs.(73.4±7.7)차/min;(8.4±2.6)차/min vs.(17.5±4.1)차/min;(10.1±3.2)차/min vs.(18.0±2.5)차/min,P균<0.05];여 FE 조상비,FP 조 T1시 HR、RR 급 T2시 RR 균명현강저[(61.3±10.3)차/min vs.(70.2±9.8)차/min;(8.4±2.6)차/min vs.(16.1±2.4)차/min;(10.1±3.2)차/min vs.(16.6±3.1)차/min,P균<0.05]。결론리다잡인연합의탁미지용우노년인무통장경검사마취효과만의,불량반응소,치득림상추엄。
Objective To assess the efficacy and safety of lidocaine combined with etomidate for the elderly patients undergoing painless colonoscopy. Methods 150 patients undergoing painless colonoscopy were randomly and equally allocated into 3 groups:lidocaine combined with etomidate(group LE,n=50),fentanyl combined with etomid-ate(group FE,n=50) and fentanyl combined with propofol(group FP,n=50). The patients received one of the three anesthetic combinations in a double-blind fashion. Colonoscopy was performed after the eyelash reflex disap-peared. MAP,RR,HR and SpO2 were monitored and recorded before the medication( T0 ) ,at the time point of examina-tion start(T1),colonoscopy getting to ileocecal valve(T2),end of operation (T3) and recovery(T4). Recovery time, the anesthesia induction time,colonoscopy time,the number of cases in which atropine and/or ephedrine were used,the anesthetic efficacy were recorded. In addition, apnea, bradycardia, hypoxemia, myoclonus, injection pain, hypotension and postoperative complications were also recorded. Results Compared with group LE, MAP, HR at T1 and RR at T1 ~T2 of group FP decreased significantly [(69. 7 ± 11. 1)mmHg vs. (88. 6 ± 11. 2)mmHg;(61. 3 ± 10. 3) /min vs. (73. 4 ± 7. 7)/min;(8. 4 ± 2. 6) /min vs. (17. 5 ± 4. 1) /min;(10. 1 ± 3. 2)/min vs. (18. 0 ± 2. 5)/min,P<0. 05]. However,compared with group FE, HR at T1 and RR in group FP significantly decreased [ ( 61. 3 ± 10. 3 )/min vs. (70. 2 ± 9. 8)/min;(8. 4 ± 2. 6)/min vs. (16. 1 ± 2. 4)/min;(10. 1 ± 3. 2)/min vs. (16. 6 ± 3. 1)/min,P<0. 05]. Conclusion Lidocaine combined with etomidate for the elderly painless colonoscopy can be considered more effective with less adverse reactions.